Monitoring of Neoadjuvant Therapy in Locally-Advanced Breast Cancer

September 28, 2015 updated by: Dartmouth-Hitchcock Medical Center
The purpose of this study is to determine whether four new alternative imaging methods can be used to follow the response of breast cancer to the treatment patients are being given. These methods produce an image of the inside of the breast so that doctors can better decide whether breast cancer is responding to therapy. An important part of the study is to examine the same person with all methods in order to directly compare results. The four methods are: MRI Elasticity Imaging (abbreviated MRE), Electrical Impedance Spectroscopy (abbreviated EIS), Microwave Imaging and Spectroscopy (abbreviated MIS), Near Infrared Spectroscopy (abbreviated NIR). In addition to the experimental imaging methods, patients may also undergo a contrast-enhanced MRI, and/or additional mammography, which will help researchers compare the experimental methods. These additional examinations are accepted diagnostic procedures; they are not experimental. Some participants will have one or both of these additional examinations if clinically indicated.

Study Overview

Status

Terminated

Study Type

Observational

Enrollment (Actual)

36

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • New Hampshire
      • Lebanon, New Hampshire, United States, 03756
        • Dartmouth-Hitchcock Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Sampling Method

Non-Probability Sample

Study Population

Women with locally-advanced breast cancer, with or without metastatic disease, meeting inclusion criteria (and giving informed consent for participation) receiving systemic therapy at DHMC will be enrolled. Breast size and epithelial integrity of the skin surface can limit the ability to deliver effective imaging exams, adn these individual characteristics need be determined in each individual patient. Women with pacemakers or other implanted electronic devices will not be allowed into the study because of potential for electrical interference with proper operation during an imaging session.

Description

Inclusion Criteria:

  1. Locally advanced breast cancer, with or without metastatic disease
  2. Patient to receive systemic therapy
  3. Breast size and epithelial integrity adequate to allow alternate imaging exams.
  4. Patient able to provide written informed consent.
  5. No serious associated psychiatric illness
  6. Age ≥ 18 years old

Exclusion Criteria:

  1. Cardiac pacemaker
  2. Any implanted electronic device
  3. Severe claustrophobia
  4. Allergy to the MRI contrast agent gadolinium

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Objective Response
Time Frame: at baseline, at conclusion of treatment (up to 6 months)
Correlate changes in each imaging modality with objective response to therapy, as defined by conventional criteria (clinical exam and conventional imaging).
at baseline, at conclusion of treatment (up to 6 months)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2006

Primary Completion (Actual)

September 1, 2015

Study Completion (Actual)

September 1, 2015

Study Registration Dates

First Submitted

April 16, 2013

First Submitted That Met QC Criteria

April 18, 2013

First Posted (Estimate)

April 23, 2013

Study Record Updates

Last Update Posted (Estimate)

September 30, 2015

Last Update Submitted That Met QC Criteria

September 28, 2015

Last Verified

September 1, 2015

More Information

Terms related to this study

Other Study ID Numbers

  • D0605

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Locally Advanced Breast Cancer

Subscribe